BiotechTube
KBio

KBio

San Diego, United States· Est.
kbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $62M

Overview

KBio is pioneering a plant-based manufacturing platform, RP3, designed to produce monoclonal antibodies and other biologics more rapidly, scalably, and sustainably than conventional CHO cell systems. The company has a preclinical pipeline targeting high-demand areas like invasive fungal infections and immuno-oncology, with programs such as KB14A for aspergillosis and candida. As a private, pre-revenue biotech, KBio's strategy is built on validating its platform through internal pipeline advancement and strategic partnerships to disrupt the biologics production landscape.

Infectious DiseaseOncologyImmunology

Technology Platform

RP3 platform uses plants as biofoundries for rapid, scalable, and sustainable production of monoclonal antibodies and other therapeutic proteins, claiming GMP material production in 8 weeks.

Funding History

2
Total raised:$62M
Series A$50M
Seed$12M

Opportunities

The global biologics manufacturing market is constrained by slow, expensive, and unsustainable CHO-based systems, creating a major opportunity for KBio's faster, more flexible, and greener plant-based platform.
The platform's speed is also uniquely suited for rapid response to pandemic threats.
Internally, its pipeline targets large, growing markets like invasive fungal infections and immuno-oncology.

Risk Factors

Key risks include unproven regulatory acceptance for plant-made human therapeutics, the challenge of achieving perfect human-like protein glycosylation in plants, and intense competition from established mammalian manufacturing and other next-gen platforms.
As a pre-revenue company, it is also highly dependent on securing continued venture financing.

Competitive Landscape

KBio competes with established mammalian CDMOs (e.g., Lonza, Samsung Biologics) and other next-generation production platforms using yeast, fungi, or cell-free systems. In plant-based manufacturing, it faces competition from companies like Leaf Expression Systems, PlantForm, and iBio, though the field is still emerging and fragmented.

More companies in Biologics / Biosimilars →More companies in United States →